메뉴 건너뛰기




Volumn 152, Issue 2, 2015, Pages 377-387

Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials

(18)  Loibl, Sibylle a,b   Jackisch, Christian b   Lederer, Bianca a   Untch, Michael c   Paepke, Stefan d   Kümmel, Sherko e   Schneeweiss, Andreas f   Huober, Jens g   Hilfrich, Jörn h   Hanusch, Claus i   Gerber, Bernd j   Eidtmann, Holger k   Denkert, Carsten l   Costa, Serban Dan m   Blohmer, Jens Uwe l   Nekljudova, Valentina a   Mehta, Keyur a   von Minckwitz, Gunter a  


Author keywords

Breast cancer; Chemotherapy; Neoadjuvant; Outcome; pCR; Survival; Young age

Indexed keywords

ANTHRACYCLINE DERIVATIVE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; TUMOR MARKER;

EID: 84946492294     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3479-z     Document Type: Article
Times cited : (85)

References (40)
  • 1
    • 84874642212 scopus 로고    scopus 로고
    • Epidemiology of breast cancer, current figures and trends
    • PID: 24771909
    • Eisemann N, Waldmann A, Katalinic A (2013) Epidemiology of breast cancer, current figures and trends. Geburtsh Frauenheilk 73:130–135
    • (2013) Geburtsh Frauenheilk , vol.73 , pp. 130-135
    • Eisemann, N.1    Waldmann, A.2    Katalinic, A.3
  • 3
    • 0022455625 scopus 로고
    • The relation between survival and age at diagnosis in breast cancer
    • COI: 1:STN:280:DyaL283osV2isg%3D%3D, PID: 3736639
    • Adami HO, Malker B, Holmberg L, Persson I, Stone B (1986) The relation between survival and age at diagnosis in breast cancer. N Engl J Med 315:559–563
    • (1986) N Engl J Med , vol.315 , pp. 559-563
    • Adami, H.O.1    Malker, B.2    Holmberg, L.3    Persson, I.4    Stone, B.5
  • 4
    • 49149119336 scopus 로고    scopus 로고
    • Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression
    • PID: 18612148
    • Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y et al (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324–3330
    • (2008) J Clin Oncol , vol.26 , pp. 3324-3330
    • Anders, C.K.1    Hsu, D.S.2    Broadwater, G.3    Acharya, C.R.4    Foekens, J.A.5    Zhang, Y.6
  • 6
    • 0036299594 scopus 로고    scopus 로고
    • Very young women (<35 years) with operable breast cancer: features of disease at presentation
    • COI: 1:STN:280:DC%2BD387ltl2gtw%3D%3D, PID: 11886005
    • Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G et al (2002) Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 13:273–279
    • (2002) Ann Oncol , vol.13 , pp. 273-279
    • Colleoni, M.1    Rotmensz, N.2    Robertson, C.3    Orlando, L.4    Viale, G.5    Renne, G.6
  • 8
    • 0036114199 scopus 로고    scopus 로고
    • Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer
    • PID: 12020397
    • Dubsky PC, Gnant MF, Taucher S, Roka S, Kandioler D, Pichler-Gebhard B et al (2002) Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer. Clin Breast Cancer 3:65–72
    • (2002) Clin Breast Cancer , vol.3 , pp. 65-72
    • Dubsky, P.C.1    Gnant, M.F.2    Taucher, S.3    Roka, S.4    Kandioler, D.5    Pichler-Gebhard, B.6
  • 9
    • 77957710541 scopus 로고    scopus 로고
    • Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
    • COI: 1:CAS:528:DC%2BC3cXht1elsLjK, PID: 20697801
    • Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM et al (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124:133–140
    • (2010) Breast Cancer Res Treat , vol.124 , pp. 133-140
    • Huober, J.1    von Minckwitz, G.2    Denkert, C.3    Tesch, H.4    Weiss, E.5    Zahm, D.M.6
  • 10
    • 84862303759 scopus 로고    scopus 로고
    • Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
    • von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796–1804
    • (2012) J Clin Oncol , vol.30 , pp. 1796-1804
    • von Minckwitz, G.1    Untch, M.2    Blohmer, J.U.3    Costa, S.D.4    Eidtmann, H.5    Fasching, P.A.6
  • 11
    • 84904188903 scopus 로고    scopus 로고
    • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
    • PID: 24529560
    • Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172
    • (2014) Lancet , vol.384 , pp. 164-172
    • Cortazar, P.1    Zhang, L.2    Untch, M.3    Mehta, K.4    Costantino, J.P.5    Wolmark, N.6
  • 12
    • 84869503259 scopus 로고    scopus 로고
    • The european society of breast cancer specialists recommendations for the management of young women with breast cancer
    • PID: 23116682
    • Cardoso F, Loibl S, Pagani O, Graziottin A, Panizza P, Martincich L et al (2012) The european society of breast cancer specialists recommendations for the management of young women with breast cancer. Eur J Cancer 48:3355–3377
    • (2012) Eur J Cancer , vol.48 , pp. 3355-3377
    • Cardoso, F.1    Loibl, S.2    Pagani, O.3    Graziottin, A.4    Panizza, P.5    Martincich, L.6
  • 13
    • 84863978873 scopus 로고    scopus 로고
    • Breast cancer in young women–a clinical challenge to be addressed in a multidisciplinary setting
    • Cardoso F, Harbeck N (2012) Breast cancer in young women–a clinical challenge to be addressed in a multidisciplinary setting. Breast Care 7:193–194
    • (2012) Breast Care , vol.7 , pp. 193-194
    • Cardoso, F.1    Harbeck, N.2
  • 14
    • 21044454272 scopus 로고    scopus 로고
    • Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group
    • von Minckwitz G, Raab G, Caputo A, Schütte M, Hilfrich J, Blohmer JU et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23:2676–2685
    • (2005) J Clin Oncol , vol.23 , pp. 2676-2685
    • von Minckwitz, G.1    Raab, G.2    Caputo, A.3    Schütte, M.4    Hilfrich, J.5    Blohmer, J.U.6
  • 15
    • 19944426993 scopus 로고    scopus 로고
    • In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study
    • von Minckwitz G, Blohmer JU, Raab G, Löhr A, Gerber B, Heinrich G et al (2005) In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 16:56–63
    • (2005) Ann Oncol , vol.16 , pp. 56-63
    • von Minckwitz, G.1    Blohmer, J.U.2    Raab, G.3    Löhr, A.4    Gerber, B.5    Heinrich, G.6
  • 16
    • 43149114454 scopus 로고    scopus 로고
    • Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study
    • von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J et al (2008) Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 100:552–562
    • (2008) J Natl Cancer Inst , vol.100 , pp. 552-562
    • von Minckwitz, G.1    Kümmel, S.2    Vogel, P.3    Hanusch, C.4    Eidtmann, H.5    Hilfrich, J.6
  • 17
    • 43149120682 scopus 로고    scopus 로고
    • Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial
    • von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J et al (2008) Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 100:542–551
    • (2008) J Natl Cancer Inst , vol.100 , pp. 542-551
    • von Minckwitz, G.1    Kümmel, S.2    Vogel, P.3    Hanusch, C.4    Eidtmann, H.5    Hilfrich, J.6
  • 18
    • 77951624086 scopus 로고    scopus 로고
    • Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from GeparQuattro study
    • COI: 1:CAS:528:DC%2BC3cXmtlSksrg%3D, PID: 20308670
    • Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H et al (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from GeparQuattro study. J Clin Oncol 28:2024–2031
    • (2010) J Clin Oncol , vol.28 , pp. 2024-2031
    • Untch, M.1    Rezai, M.2    Loibl, S.3    Fasching, P.A.4    Huober, J.5    Tesch, H.6
  • 19
    • 67649921349 scopus 로고    scopus 로고
    • Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer
    • PID: 19364964
    • Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I et al (2009) Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol 27:2938–2945
    • (2009) J Clin Oncol , vol.27 , pp. 2938-2945
    • Untch, M.1    Möbus, V.2    Kuhn, W.3    Muck, B.R.4    Thomssen, C.5    Bauerfeind, I.6
  • 20
    • 80052414508 scopus 로고    scopus 로고
    • PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer–results at the time of surgery
    • COI: 1:STN:280:DC%2BC3MfptFClug%3D%3D, PID: 21385882
    • Untch M, Fasching PA, Konecny GE, von Koch F, Conrad U, Fett W et al (2011) PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer–results at the time of surgery. Ann Oncol 22:1988–1998
    • (2011) Ann Oncol , vol.22 , pp. 1988-1998
    • Untch, M.1    Fasching, P.A.2    Konecny, G.E.3    von Koch, F.4    Conrad, U.5    Fett, W.6
  • 21
    • 80052401850 scopus 로고    scopus 로고
    • PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer–outcome on prognosis
    • COI: 1:STN:280:DC%2BC3MfptFCltQ%3D%3D, PID: 21382868
    • Untch M, von Minckwitz G, Konecny GE, Conrad U, Fett W, Kurzeder C et al (2011) PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer–outcome on prognosis. Ann Oncol 22:1999–2006
    • (2011) Ann Oncol , vol.22 , pp. 1999-2006
    • Untch, M.1    von Minckwitz, G.2    Konecny, G.E.3    Conrad, U.4    Fett, W.5    Kurzeder, C.6
  • 22
    • 79957601951 scopus 로고    scopus 로고
    • Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups
    • COI: 1:CAS:528:DC%2BC3MXhtlWisLbM, PID: 21788566
    • Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R et al (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29:3351–3357
    • (2011) J Clin Oncol , vol.29 , pp. 3351-3357
    • Untch, M.1    Fasching, P.A.2    Konecny, G.E.3    Hasmüller, S.4    Lebeau, A.5    Kreienberg, R.6
  • 23
    • 78651081149 scopus 로고    scopus 로고
    • Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
    • von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S et al (2011) Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 125:145–156
    • (2011) Breast Cancer Res Treat , vol.125 , pp. 145-156
    • von Minckwitz, G.1    Untch, M.2    Nüesch, E.3    Loibl, S.4    Kaufmann, M.5    Kümmel, S.6
  • 25
    • 84856444501 scopus 로고    scopus 로고
    • Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
    • COI: 1:CAS:528:DC%2BC38XitVSmurc%3D, PID: 22257523
    • Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU et al (2012) Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 13:135–144
    • (2012) Lancet Oncol , vol.13 , pp. 135-144
    • Untch, M.1    Loibl, S.2    Bischoff, J.3    Eidtmann, H.4    Kaufmann, M.5    Blohmer, J.U.6
  • 26
    • 0035425528 scopus 로고    scopus 로고
    • Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study
    • von Minckwitz G, Costa SD, Raab G, Blohmer JU, Eidtmann H, Hilfrich J et al (2001) Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J Clin Oncol 19:3506–3515
    • (2001) J Clin Oncol , vol.19 , pp. 3506-3515
    • von Minckwitz, G.1    Costa, S.D.2    Raab, G.3    Blohmer, J.U.4    Eidtmann, H.5    Hilfrich, J.6
  • 27
    • 84946504656 scopus 로고    scopus 로고
    • Accessed 02 Feb 2015
    • http://www.ago-online.de/fileadmin/downloads/leitlinien/mamma/march2012/14_2012E_Breast_Cancer_Specific_Situations.pdf Accessed 02 Feb 2015
  • 28
    • 84946504657 scopus 로고    scopus 로고
    • Accessed 02 Feb 2015
    • http://www.ago-online.de/fileadmin/downloads/leitlinien/mamma/march2012/13_2012E_Adjuvant_Radiotherapy.pdf Accessed 02 Feb 2015
  • 29
    • 20044377408 scopus 로고    scopus 로고
    • Patterns of treatment effects in subsets of patients in clinical trials
    • PID: 15208206
    • Bonetti M, Gelber RD (2004) Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics 5:465–481
    • (2004) Biostatistics , vol.5 , pp. 465-481
    • Bonetti, M.1    Gelber, R.D.2
  • 30
    • 80054005684 scopus 로고    scopus 로고
    • Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy
    • PID: 21900114
    • Arvold ND, Taghian AG, Niemierko A, Abi Raad RF, Sreedhara M, Nguyen PL et al (2011) Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 29:3885–3891
    • (2011) J Clin Oncol , vol.29 , pp. 3885-3891
    • Arvold, N.D.1    Taghian, A.G.2    Niemierko, A.3    Abi Raad, R.F.4    Sreedhara, M.5    Nguyen, P.L.6
  • 31
    • 84857700943 scopus 로고    scopus 로고
    • Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling
    • COI: 1:CAS:528:DC%2BC38Xjt1Wltb4%3D, PID: 22261811
    • Azim HA Jr, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M et al (2012) Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res 18:1341–1351
    • (2012) Clin Cancer Res , vol.18 , pp. 1341-1351
    • Azim, H.A.1    Michiels, S.2    Bedard, P.L.3    Singhal, S.K.4    Criscitiello, C.5    Ignatiadis, M.6
  • 32
    • 84856636292 scopus 로고    scopus 로고
    • Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials
    • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432–444
    • (2012) Lancet , vol.379 , pp. 432-444
    • Peto, R.1    Davies, C.2    Godwin, J.3    Gray, R.4    Pan, H.C.5    Clarke, M.6
  • 33
    • 84886615995 scopus 로고    scopus 로고
    • Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial
    • COI: 1:CAS:528:DC%2BC3sXhtlCqs7bP, PID: 23752109
    • Partridge AH, Gelber S, Piccart-Gebhart MJ, Focant F, Scullion M, Holmes E et al (2013) Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol 31:2692–2698
    • (2013) J Clin Oncol , vol.31 , pp. 2692-2698
    • Partridge, A.H.1    Gelber, S.2    Piccart-Gebhart, M.J.3    Focant, F.4    Scullion, M.5    Holmes, E.6
  • 34
    • 34347223994 scopus 로고    scopus 로고
    • Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea–a report from the Korean Breast Cancer Society
    • PID: 17515570
    • Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS et al (2007) Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea–a report from the Korean Breast Cancer Society. J Clin Oncol 25:2360–2368
    • (2007) J Clin Oncol , vol.25 , pp. 2360-2368
    • Ahn, S.H.1    Son, B.H.2    Kim, S.W.3    Kim, S.I.4    Jeong, J.5    Ko, S.S.6
  • 35
    • 85181122894 scopus 로고    scopus 로고
    • Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
    • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Godwin J, Gray R, Clarke M, Cutter D, Darby S et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784
    • (2011) Lancet , vol.378 , pp. 771-784
    • Godwin, J.1    Gray, R.2    Clarke, M.3    Cutter, D.4    Darby, S.5
  • 37
    • 84921838679 scopus 로고    scopus 로고
    • Adjuvant ovarian suppression in premenopausal breast cancer
    • COI: 1:CAS:528:DC%2BC2MXisFGrtb4%3D, PID: 25495490
    • Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M et al (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372:436–446
    • (2015) N Engl J Med , vol.372 , pp. 436-446
    • Francis, P.A.1    Regan, M.M.2    Fleming, G.F.3    Láng, I.4    Ciruelos, E.5    Bellet, M.6
  • 38
    • 0345963033 scopus 로고    scopus 로고
    • Factors influencing the effect of age on prognosis in breast cancer: population based study
    • COI: 1:STN:280:DC%2BD3c7ktlKitw%3D%3D, PID: 10678859
    • Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M (2000) Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 320:474–478
    • (2000) BMJ , vol.320 , pp. 474-478
    • Kroman, N.1    Jensen, M.B.2    Wohlfahrt, J.3    Mouridsen, H.T.4    Andersen, P.K.5    Melbye, M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.